Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pharmacokinetic and Safety Study of Proposed Abatacept Biosimilar DRL_AB in Healthy Males
NCT07744828Phase 1Not yet recruiting
- Sponsor
- Dr. Reddy's Laboratories
- Start
- Aug 2026
- Primary completion
- Dec 2026
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of abatacept in rheumatoid arthritis (RA) (2 arms), sponsored by Dr. Reddy's Laboratories. Primary endpoints: Area Under the Serum Concentration Versus Time Curve From Time 0 Extrapolated to Time t, Maximum Measured Serum Concentration and 1 more. Planned start Aug 2026; status: not yet recruiting.
02
Drugs
abatacept
03
Conditions
rheumatoid arthritis (RA)
Beyond the preview
Go deeper on NCT07744828.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07744828.